AGIO Stock Agios Pharmaceuticals, Inc.
US · NasdaqGSLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Focused rare-disease portfolio and positive analyst coverage offer meaningful catalyst-driven upside.
Future value: $50.00 (+43.27%) · 6-12 months
Signal breakdown
- ▸Bank of America maintained Buy with a $50 target.
- ▸Above 50-day MA (+5.56%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.77× average — accumulation
- ▸~43% upside to price target
Is AGIO a buy right now?
Trend: AGIO is trading above the 50-day average (+10.71%), RSI 63 — neutral momentum, with a 3-month return of +0.08%.
Valuation & quality: Agios Pharmaceuticals, Inc. trades on forward P/E -9.1, price-to-book 2.14; fundamentals show net margin 0.0%, return on equity -34.3%, revenue growth 259.3% year on year.
Analyst consensus: 8 analysts have a mean 12-month price target of $45.88 (+24.5% vs the last close; range $32.00 – $72.00), consensus rating “buy”.
Our screen: STRONG BUY (score 6) — Focused rare-disease portfolio and positive analyst coverage offer meaningful catalyst-driven upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +11.90% | -17.20% | +5.00% | +26.20% | -19.10% | +12.20% | -1.30% | +11.30% |
Fundamentals
Analyst price target
Technical signals
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 539 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.